Real-time · AI · Cross-signal
Nanostics & OncoHelix just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Nanostics & OncoHelix, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Nanostics and OncoHelix Partner to Provide ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the Middle East
Sep 26, 2024•over 1 year ago
Contract Type
partnership
Description
Nanostics Inc. and OncoHelix have announced their partnership to provide ClarityDX Prostate to healthcare providers and men in the Middle East. ClarityDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, providing critical support in making more informed decisions about further medical procedures.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months